NewAmsterdam Pharma Co N.V.
NAMSW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001936258
In the last 90 days, NewAmsterdam Pharma Co N.V. insiders filed 1 open-market purchase and 3 sales; 9 institutions reported holding it in 13F filings for Q2 2026, worth $28.1M in total; no superinvestor holds it.
Other share classesNAMS
13F holders, Q1 2023
Institutional positions in NewAmsterdam Pharma Co N.V. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- −3 vs. Q4 2022
- Shares held
- 1.57M
- −363.1K (−18.8%) vs. Q4 2022
- Total value
- $4.12M
- +$2.21M (+115.3%) vs. Q4 2022
- New holders
- 2
- 0 more added
- Sold out
- 5
- 4 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NAMSW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 9 | $28.1M |
| Q1 2026 | 9 | $26.0M |
| Q4 2025 | 9 | $29.9M |
| Q3 2025 | 9 | $22.2M |
| Q2 2025 | 10 | $10.4M |
| Q1 2025 | 10 | $12.3M |
| Q4 2024 | 11 | $18.8M |
| Q3 2024 | 11 | $9.32M |
| Q2 2024 | 10 | $11.5M |
| Q1 2024 | 11 | $15.9M |
| Q4 2023 | 18 | $4.91M |
| Q3 2023 | 19 | $2.88M |
| Q2 2023 | 19 | $3.94M |
| Q1 2023 | 19 | $4.12M |
| Q4 2022 | 22 | $1.91M |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 1 | $35.5K |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding NewAmsterdam Pharma Co N.V.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Mint Tower Capital Management B.V. | 6,533 | $12.0K | 0.00% | 00.0% | Unchanged |
| Vestcor Inc | 9,632 | $18.0K | 0.00% | 00.0% | Unchanged |
| Walleye Trading LLC | 14,956 | $27.5K | 0.00% | −1,400−8.6% | Reduced |
| Laurion Capital Management LP | 16,666 | $30.7K | 0.00% | 00.0% | Unchanged |
| PEAK6 Investments LLC | 17,000 | $31.3K | 0.00% | −23,033−57.5% | Reduced |
| Clear Street LLC | 17,619 | $32.4K | 0.01% | +17,619 | New |
| Caxton Corp | 21,333 | $40.5K | 0.10% | 00.0% | Unchanged |
| Walleye Capital LLC | 25,986 | $47.8K | 0.00% | −2,402−8.5% | Reduced |
| HRT Financial LP | 30,321 | $56.0K | 0.00% | 00.0% | Unchanged |
| Westchester Capital Management, LLC | 31,189 | $57.7K | 0.00% | 00.0% | Unchanged |
| Affinity Asset Advisors, LLC | 37,000 | $68.5K | 0.03% | +37,000 | New |
| Deerfield Management Company, L.P. (Series C) | 92,787 | $170.7K | 0.00% | 00.0% | Unchanged |
| Exos TFP Holdings LLC | 93,932 | $172.8K | 0.04% | −43,385−31.6% | Reduced |
| Bain Capital Life Sciences Investors, LLC | 100,000 | $184.0K | 0.02% | 00.0% | Unchanged |
| Ensign Peak Advisors, Inc | 150,000 | $277.5K | 0.00% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 333,333 | $613.3K | 0.01% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 500,333 | $920.6K | 0.07% | 00.0% | Unchanged |
| Highbridge Capital Management LLC | – | $1.36M | 0.06% | – | – |
| EcoR1 Capital, LLC | 66,665 | – | – | 00.0% | Unchanged |
| Castle Creek Arbitrage, LLC | 0 | $0 | 0.00% | −51,520−100.0% | Sold out |
| DuPont Capital Management Corp | 0 | $0 | 0.00% | −8,333−100.0% | Sold out |
| Wolverine Asset Management LLC | 0 | $0 | 0.00% | −1,462−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −1,076−100.0% | Sold out |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −285,105−100.0% | Sold out |